CDER director
This article was originally published in The Tan Sheet
Executive Summary
Janet Woodcock is named director of the Center for Drug Evaluation and Research, where she has served as acting director for six months, the agency says March 10. She previously served as FDA's chief medical officer and as a deputy commissioner. An internist and rheumatologist, Woodcock has held other leadership positions at FDA, including Office of Therapeutics Research and Review director and Center for Biologics Evaluation and Research acting deputy director as well as previous service as CDER director (1"The Tan Sheet" Dec. 10, 2007, In Brief). The Safety First program CDER launched this month is one initiative Woodcock has led since becoming acting CDER director (2"The Tan Sheet" March 3, 2008, p. 9). She also led the agency's launch of the Critical Path Initiative, designed to bridge the gap between basic scientific research and the medical product development process...
You may also be interested in...
FDA “Safety First” Initiative, Agency’s Requests Draw Doubts From DeLauro
FDA is implementing the Safety First initiative to "ensure that significant post-market safety issues are our highest priority," according to acting Center for Drug Evaluation and Research Director Janet Woodcock
CDER seeks director
FDA is seeking a director for its Center for Drug Evaluation and Research following the October departure of Steven Galson, the agency announces Dec. 3. Accepting applications through Feb. 1, FDA is seeking a candidate who will lead the agency in defining "drug regulatory policy for the next generation," and expediting review of applications for new drug applications, among other goals, FDA notes. Former CDER director Janet Woodcock is filling the role on a temporary basis...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”